Autoimmune-Summaries: Daily Autoimmune Updates at a Glance
- decodeMR Team
- 21 hours ago
- 1 min read
19/05/2026
UCB announced week 16 data from the BE BOLD study in PsA (Ref)
UCB announced data from the Phase 3, BE BOLD/ NCT06624228 study which compared the efficacy of BIMZELX®(bimekizumab; Anti-IL-17A and anti-IL-17F) versus SKYRIZI®(risankizumab; Anti-IL-23) after 16 weeks of treatment in participants with active psoriatic arthritis (PsA).
The study met its primary endpoint of belimumab superiority in ACR50 at Week 16, which was achieved by 49.1% receiving bimekizumab vs 38.4% of those receiving risankizumab, with statistical significance (p=0.0078).
Numerically greater responses without statistical significance were observed for bimekizumab vs risankizumab across all secondary endpoints.
The secondary endpoint of ACR50 at Week 4 was achieved in 19.9% of those receiving bimekizumab vs 7.2% of those receiving risankizumab.
53.4% of those receiving bimekizumab and 46.6% receiving risankizumab achieved the PASI100 exploratory endpoint at Week 16.
No new safety signals were identified, and overall safety profiles were comparable between treatments, except for Candida infections which were more frequent for bimekizumab.
